ESMO Congress | Conference

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

October 1st 2020

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Apalutamide Maintains Health-Related QoL Among Men With Nonmetastatic CRPC

September 25th 2020

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Dr. Nixon on the Role of MSI in Cancer

September 24th 2020

Andrew B. Nixon, PhD, ​MBA, discusses the role of microsatellite instability in cancer.

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Nivolumab/Chemo Improves PFS, Elicits Durable Responses in Gastric/GEJ Cancers

September 21st 2020

The addition of nivolumab to chemotherapy resulted in a statistically significant improvement in progression-free survival and elicited higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

September 21st 2020

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.